Probiotics in the management of irritable bowel syndrome: A review of clinical trials
Probiotics in the management of irritable bowel syndrome: A review of clinical trials
复制标题
DOI：
10.1080/089106001753341282
复制
发表时间：
2001-12-01
影响因子：
--
通讯作者：
Hamilton-Miller, J. M. T.
中科院分区：
文献类型：
--
作者：
Hamilton-Miller, J. M. T.
肠易激综合症是一种病因不明的常见病症，其医疗治疗效果并不令人满意。尽管有证据表明肠道菌群紊乱可能是导致痛苦症状的发生和/或长期存在的原因，但很少有人注意到使用益生菌纠正这种不平衡的潜在优势。已审查了 12 项临床试验的结果，共涉及 1371 名患者，其中接受了益生菌治疗。在 10 项研究中（其中 5 项是随机、双盲和安慰剂对照），使用益生菌是有益的。各项研究中的益生菌制剂、剂量和治疗持续时间差异很大。尽管在研究设计和发表细节方面存在一些缺陷，但现在似乎有足够的证据表明这种廉价且安全的治疗方式的治疗效果可以得到更广泛的测试。
Irritable bowel syndrome is a common condition of unknown aetiology, the medical management of which is unsatisfactory. Despite evidence that a disturbance of intestinal flora may be responsible for the initiation and/or chronicity of the distressing symptoms, little attention has been paid to the potential advantages of correcting this imbalance by using probiotics. Results of 12 clinical trials, involving 1371 patients in all, in which probiotic treatment was given have been reviewed. In 10 (five of which were randomized, double-blind and placebo controlled), use of probiotics was beneficial. The probiotic agents, dosage and duration of treatment varied widely between the studies. Despite several shortcomings in terms of study design and publication details, there now seems to be sufficient evidence of the therapeutic efficacy for this inexpensive and safe treatment modality to be tested more widely.